Will March 2012 Mark The End Of Regulatory Limbo For Discovery’s Surfaxin?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Discovery Laboratories now believes March 2012 could mark the end of an almost eight-year regulatory odyssey to secure FDA approval of its synthetic surfactant Surfaxin (lucinactant).